Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Other financing activities (2016)

Outlook Therapeutics (OTLK) has disclosed Other financing activities for 2 consecutive years, with $176086.0 as the latest value for Q3 2017.

  • On a quarterly basis, Other financing activities changed N/A to $176086.0 in Q3 2017 year-over-year; TTM through Sep 2017 was $216086.0, a N/A change, with the full-year FY2023 number at $823894.0, up 37.32% from a year prior.
  • Other financing activities was $176086.0 for Q3 2017 at Outlook Therapeutics, up from $40000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $176086.0 in Q3 2017 to a low of $40000.0 in Q4 2016.